Table 4.

Management of CRRTa

SiteRespondents Using CRRTCRRT Modalities Used (n [%] of Respondents)Weight-Based DosingNon–Weight-Based Dosing
AV ModalitiesCVVHCVVHDCVVHDFn (%)Median Dosage (ml/kg per h)n (%)Median Dosage (ml/h)
VA sites
    A51 (20.0)5 (100.0)5 (100.0)2000
    B22 (100.0)2 (100.0)NR
    C31 (33.3)3 (100.0)2 (66.7)351 (3.33)1850
    E44 (100.0)2 (50.0)2 (50.0)1 (25.0)353 (75.0)1000
    F32 (66.7)1 (33.3)1 (33.3)1 (33.3)3 (100.0)1000
    H81 (12.5)2 (25.0)8 (100.0)8 (100.0)1000
    I43 (75.0)3 (75.0)4 (100.0)4 (100.0)2500
    K62 (33.3)4 (66.7)6 (100.0)2000
    L31 (33.3)1 (33.3)2 (66.7)1 (33.3)252 (66.7)1800
    M32 (66.7)3 (100.0)3 (100.0)3 (100.0)1100
    N11 (100.0)1 (100.0)1500
    P55 (100.0)5 (100.0)4 (80.0)4 (100.0)NR
    all VA473 (6.4)22 (46.8)31 (66.0)23 (48.9)4 (8.5)3542 (89.4)1800
Non-VA sites
    Qbbbbbb2000
    R44 (100)4 (100.0)1500
    S54 (80)1 (20)5 (100.0)1600
    T72 (28.6)7 (100.0)2 (28.6)7 (100.0)5 (71.4)352 (28.6)1000
    U1313 (100.0)13 (100.0)13 (100.0)2400
    V53 (60.0)3 (60.0)5 (100.0)1000
    W112 (18.2)2 (18.2)9 (81.8)4 (36.4)1 (9.1)3510 (90.9)1500
    all non-VA454 (8.9)13 (28.9)32 (71.1)27 (60.0)6 (13.3)3539 (86.7)1600
Combined VA/non-VA sites
    X82 (25.0)3 (37.5)4 (50.0)6 (75.0)5 (62.5)353 (37.5)2250
    Y125 (41.7)11 (91.7)11 (91.7)5 (41.7)357 (58.3)2300
    all combined202 (10.0)8 (40.0)15 (75.0)17 (85.0)10 (50.0)3510 (50.0)2400
All sites1129 (8.0)43 (38.4)78 (69.6)67 (59.7)20 (17.9)35 (IQR 35 to 35)91 (81.2)1825 (IQR 1200 to 2400)
  • a CVVH, continuous venovenous hemofiltration; CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous venovenous hemodiafiltration.

  • b Site provided aggregate data for all practitioners.